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Epidermal keratinocyte-derived overexpression of
vascular endothelial growth factor has been function-
ally linked to increased density of tortuous and
hyperpermeable dermal microvessels, representing a
characteristic component of cutaneous in¯ammation.
We hypothesized that potent anti-in¯ammatory
properties of synthetic glucocorticoids are attributed
in part to their interference with the regulated
vascular endothelial growth factor expression by
keratinocytes. As vascular endothelial growth factor
is markedly upregulated by autocrine transforming
growth factor a and paracrine hepatocyte growth
factor/scatter factor expression, the effect of
glucocorticoids on growth-factor-induced vascular
endothelial growth factor production by primary
and immortalized keratinocytes was examined.
Glucocorticoids were shown to suppress vascular
endothelial growth factor protein and mRNA expres-
sion in a concentration- and time-dependent fashion.
In transcriptional activation studies, however, com-
mon 5¢-regulatory regions of the vascular endothelial
growth factor gene failed to confer inhibitory gluco-
corticoid effects. Instead, glucocorticoids were
shown to increase vascular endothelial growth factor
mRNA turnover, indicating that post-transcriptional
modes of glucocorticoid action are employed to
negatively regulate induced vascular endothelial
growth factor expression. Together, these studies
identify vascular endothelial growth factor upregula-
tion by epidermal keratinocytes as a putative target
of glucocorticoid action in cutaneous in¯ammation.
Our data provide strong evidence that mRNA
destabilization may represent a mechanism by which
glucocorticoids inhibit growth-factor-regulated
vascular endothelial growth factor gene expression
by keratinocytes. Key words: angiogenesis factors/
gene expression regulation/glucocorticoids/in¯ammation/
keratinocytes. J Invest Dermatol 117:1581±1587, 2001
A
ngiogenesis is a multiphase process, leading to blood
vessel formation as a result of new capillary sprouting
and/or remodeling of a preexisting vascular network
(Risau, 1997; Yancopoulos et al, 2000). Whereas the
adult skin vasculature for the most part is quiescent
due to the dominant in¯uence of endogenous angiogenesis
inhibitors over angiogenic factors (Detmar, 1996), skin angiogen-
esis can be rapidly initiated by a ``pro-angiogenic imbalance''
during wound healing and numerous diseases, including in¯am-
matory skin disorders (e.g., psoriasis, allergic contact dermatitis) and
cutaneous neoplasias (e.g., squamous cell carcinoma, malignant
melanoma) (Detmar, 2000).
Recent advances in vascular biology identi®ed a number of key
molecules that direct angiogenic responses (Carmeliet and Jain,
2000), among which vascular endothelial growth factor (VEGF/
VPF) is considered the major skin angiogenesis factor (Detmar,
2000). VEGF/VPF is expressed at low levels in healthy skin and is
markedly upregulated by epidermal keratinocytes in in¯ammatory
skin diseases, closely associated with vascular hyperpermeability and
neovascularization (Detmar et al, 1994; Brown et al, 1995a; 1995b).
Keratinocyte-derived VEGF/VPF is a strong and selective mitogen
for dermal microvascular endothelial cells (Detmar et al, 1995).
Furthermore, transgenic targeted VEGF/VPF overexpression to
basal keratinocytes results in enhanced density of tortuous and
hyperpermeable dermal capillaries, further substantiating the role of
VEGF/VPF as a principal skin angiogenesis factor (Detmar et al,
1998). VEGF/VPF expression in epidermal keratinocytes may be
strongly induced by autocrine expression of transforming growth
factor a (TGF-a) and other ligands of the epidermal growth factor
receptor (Detmar et al, 1994; Gille et al, 1997), or by mesenchymal
cell-derived hepatocyte growth factor/scatter factor (HGF/SF)
(Gille et al, 1998; Wojta et al, 1999) and keratinocyte growth factor
(Frank et al, 1995) in a paracrine fashion. In addition, skin hypoxia
acts as central stimulus for VEGF/VPF gene expression by
epidermal keratinocytes (Detmar et al, 1997). The latter induction
pathway seems to be critical in areas of cutaneous neoplasia in close
proximity to tumor necrosis and during wound healing, whereas
growth factors such as TGF-a and HGF/SF may function as
predominant stimuli for keratinocyte VEGF/VPF upregulation in
in¯ammatory skin diseases (Detmar, 2000).
Therapeutically, synthetic glucocorticoids (GC) belong to the
most potent anti-in¯ammatory agents currently available and
remain the mainstay for many chronic in¯ammatory skin diseases,
including atopic and contact dermatitis, or bullous diseases and
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psoriasis (Baumann and Kerdel, 1999; Werth and Lazarus, 1999).
Most of the powerful anti-in¯ammatory actions of GC are
accounted for by direct and indirect effects of reduced expression
of adhesion molecules, cytokines and chemokines, both on resident
and migratory cells (Newton, 2000). Given the strong contribution
of VEGF/VPF upregulation by epidermal keratinocytes to skin
angiogenesis in numerous cutaneous in¯ammatory diseases (Detmar
et al, 1994; Brown et al, 1995a; 1995b), we hypothesized that
known anti-in¯ammatory properties of GC are attributed in part to
their interference with the regulated VEGF/VPF expression by
epidermal keratinocytes. We thus examined the effects of GC as
potent inhibitors of in¯ammatory processes on TGF-a- and HGF/
SF-induced VEGF/VPF expression by keratinocytes in vitro.
We herein demonstrate that GC suppress growth-factor-induced
VEGF/VPF expression by keratinocytes in a time- and concen-
tration-dependent fashion. These ®ndings are in accordance with
previous reports, revealing GC-mediated inhibition of basal and
hypoxia-induced VEGF/VPF expression by rat glioma cells (Heiss
et al, 1996; Machein et al, 1999), or downregulation of platelet-
derived growth-factor-induced expression by vascular smooth
muscle cells (Nauck et al, 1998). Extending on these observations,
we explored molecular mechanisms that mediate inhibitory effects
on VEGF/VPF gene upregulation. These studies revealed that
reporter gene constructs spanning ±2279/+957 bp of the VEGF/
VPF gene 5¢-regulatory region fail to confer GC-mediated
suppression. As an alternative mechanism, GC signi®cantly
decreased VEGF/VPF mRNA stability, indicating that enhanced
mRNA turnover may, at least in part, account for inhibition of
keratinocyte VEGF/VPF expression by GC.
MATERIALS AND METHODS
Reagents Human recombinant TGF-a and HGF/SF were purchased
from R&D Systems (Wiesbaden, Germany). Actinomycin D,
dexamethasone, clobetasol, and hydrocortisone were obtained from
Sigma Chemicals (Deisenhofen, Germany).
Cells and culture conditions HaCaT cells (utilized between passages
45 and 55; generously provided by Prof. Dr. Norbert E. Fusenig;
German Cancer Research Center, Division of Carcinogenesis and
Differentiation, Heidelberg, Germany) (Boukamp et al, 1988) were
cultured at 37°C and 5% CO2 in Dulbecco's modi®ed Eagle's medium
(DMEM; Gibco Life Technologies, Karlsruhe, Germany), supplemented
with 10% fetal bovine serum (Gibco), 2 mM glutamine (Gibco), 100 U
per ml penicillin (Gibco), 100 mg per ml streptomycin (Gibco), and
250 mg per ml amphotericin B (Gibco). Human adult epidermal
keratinocytes (Clonetics, BioWhittaker Europe, Taufkirchen, Germany)
were propagated in serum-free keratinocyte growth medium (KGM-2,
Clonetics). For all experiments, primary keratinocytes were used at
passage 2 and 3.
VEGF/VPF protein quanti®cation For quantitative determination of
human VEGF/VPF concentrations in cell culture supernatants, the
QuantikineÔ Human VEGF Immunoassay from R&D Systems was
utilized. Cell cultures were grown in 12-well plates to con¯uence and
rendered quiescent by changing to serum-free DMEM (HaCaT cells) or
to KGM-2 without supplements (keratinocytes) for 24 h. Cells were
then incubated with different concentrations of the respective
recombinant human growth factors and/or GC for indicated time
periods in fresh medium. Experiments were performed in triplicate
(n = 3), and results are expressed as mean 6 SD. Total cellular protein
was harvested by addition of 5 M sodium hydroxide followed by a
freeze±thaw cycle. Subsequently, protein concentration was determined
using the DC Protein Standard Assay (Bio-Rad, MuÈnchen, Germany).
For statistical analysis Student's t tests were performed.
RNA extraction and northern blot analysis Total cellular RNA was
isolated from con¯uent cell cultures grown in six-well plates by the
RNeasy Mini Procedure (Qiagen, Hilden, Germany) after
homogenization of cell lysates employing the QIAshredder (Qiagen).
Twenty micrograms of total cellular RNA were fractionated on 1%
agarose/6.6% formaldehyde gels, transferred to nylon membranes (Nytran
plus, Schleicher & Schuell, Dassel, Germany) using an electroblotting
chamber (Trans Blot Cell; Bio-Rad), and covalently linked by ultraviolet
irradiation (UV Stratalinker 2400; Stratagene, Amsterdam Zuidoost,
Netherlands). Membranes were prehybridized at 65°C for 30 min in
Rapid-hyb buffer (Amersham Life Science, Freiburg, Germany).
Hybridization was performed at 65°C for 2 h using the Rapid-hyb
buffer containing approximately 0.5 3 106 cpm per ml of [a-32P]-
labeled DNA probe (speci®c activity > 109 cpm per mg DNA).
Membranes were washed twice with 0.1% sodium dodecyl sulfate/0.1 3
sodium citrate/chloride buffer for 20±30 min at 60°C and exposed to X-
ray ®lm with intensifying screens at ±70°C for 1 d. [a-32P]-labeled
probes were prepared by using random primer oligonucleotides
(rediprime DNA labeling system, Amersham). A 303 bp fragment
encompassing coding sequences of exon 1 to exon 3 (nucleotides 67±
370; GenBank accession number M32977) of the human VEGF/VPF
cDNA (Tischer et al, 1989) and a 502 bp coding sequence of the human
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA
(nucleotides 286±788; GenBank accession number M33197) were used
as speci®c probes. Autoradiographs and prints were scanned on an HP
ScanJet 6100C scanner (Hewlett Packard, BoÈblingen, Germany) utilizing
the HP DeskScan II program (Hewlett Packard). Digitized images were
processed by Microsoft software programs (Microsoft Powerpoint and
Word; Microsoft, Redmond, WA) and printed on a laser printer. Each
image is derived from a representative autoradiograph and depicts
characteristic band and background densities.
Analysis of VEGF/VPF mRNA stability After stimulation with
100 ng per ml HGF/SF for 16 h either in the absence or presence of
dexamethasone, the transcription inhibitor actinomycin D was added to
the cell cultures at a ®nal concentration of 7.5 mg per ml (time point
designated 0). Total RNA was extracted at time point 0 and every hour
during the following 3 h after addition of actinomycin D. Subsequent
northern blot analyses were performed as described above.
Autoradiographs and prints were scanned on an HP ScanJet 6100C
scanner (Hewlett Packard) utilizing the HP DeskScan II program
(Hewlett Packard). Densitometry was performed on digitized images of
the autoradiographs and images of the respective ethidium-bromide-
stained nylon membrane utilizing the Optimas6.0 program (Optimas,
Bothwell, WA). The quantity of VEGF/VPF mRNA expression at each
time point was corrected for loading differences with respect to the
amount of 28S rRNA. The half-life of VEGF/VPF mRNA was
determined by calculating linear regressions to a log-linear plot of
mRNA expression versus time (SigmaPlot, SPSS, Chicago, IL).
Reporter gene constructs The different VEGF/VPF CAT constructs
have been described and analyzed previously (Gille et al, 1997). Brie¯y,
the 5¢-deletional reporter gene plasmids were generated by inserting the
corresponding promoter sequences into the pCAT basic vector from
Promega (Mannheim, Germany). The DNA fragments (including
¯anking 5¢-Hind III and 3¢-Xho I enzyme restriction sites to facilitate
directional cloning into the parent vector) were synthesized by the
polymerase chain reaction technique. The ±2279/+957 bp VEGF/VPF
luciferase construct (original designation ±3317/±81 bp) was kindly
provided by Dr. Georg Breier (Ikeda et al, 1995).
Transient transfection and analysis of reporter gene
expression Cells were transfected with 5 mg of appropriate CAT
reporter using the SuperFect Transfection Reagent (Qiagen). Twenty-
four hours prior to transfection, 5 3 105 cells were seeded per 60 mm
dish, yielding »50% con¯uence on the day of transfection. Twenty-four
hours after transfection, control transfectants were left untreated (media
change) and test transfectants were exposed to TGF-a or HGF/SF (each
at 100 ng per ml) in the absence or presence of dexamethasone (10±5
M). Sixteen hours later, lysates were prepared by rapid freeze±thaw
cycles. Quantitative determination of chloramphenicol acetyl transferase
(CAT) expression was performed by colorimetric enzyme immunoassay
(CAT ELISA, Roche Molecular Biochemicals, Mannheim, Germany).
CAT expression was normalized to the activity of the cotransfected pSV-
b-galactosidase control vector (2 mg, Promega). b-Galactosidase activity
was determined by enzyme-linked immunosorbent assay using the
Enzyme Assay System from Promega. Luciferase constructs were
transfected by electroporation (Gene Pulser II, Bio-Rad). HaCaT cells
(4.5 3 106) were exposed to 15 mg appropriate ®re¯y luciferase reporter
and 3 mg pRL-SV40 plasmid (Promega) during electroporation. Twenty-
four hours after transfection, cells were treated as detailed above. The
activities of ®re¯y and Renilla luciferases were measured sequentially by
the Lumat LB 9507 (Berthold Technologies, Bad Wildbad, Germany)
utilizing the Promega's Dual-Luciferase Reporter (DLR) Assay System.
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RESULTS
Inhibitory effects of dexamethasone on the TGF-a- and
HGF/SF-induced VEGF/VPF protein expression by
cultured keratinocytes To evaluate whether GC affect the
regulated VEGF/VPF expression in cultured keratinocytes, the
effects of dexamethasone on VEGF/VPF protein expression in
supernatants of TGF-a- and HGF/SF-stimulated cells were
analyzed. Initial studies on primary epidermal keratinocytes
revealed signi®cant inhibition of both TGF-a- and HGF/SF-
induced VEGF/VPF protein synthesis at micromolar
concentrations (10±6 M, Fig 1a). For dose±response studies,
immortalized HaCaT cells were exposed to increasing
concentrations of dexamethasone in the presence of either TGF-
a (Fig 1b) or HGF/SF (Fig 1c). The applied concentrations of the
respective stimuli have been shown previously to maximally induce
VEGF/VPF protein expression in both primary keratinocytes and
HaCaT cells (Detmar et al, 1994; Gille et al, 1998). These dose±
response studies revealed attenuation of TGF-a-induced VEGF/
VPF protein expression at 10±9 M of dexamethasone and signi®cant
inhibition at 10±7 M (Fig 1b), whereas the HGF/SF-regulated
VEGF/VPF protein secretion by HaCaT cells was greatly reduced
at 10±9 M, with maximal inhibitory effects seen at 10±7 M (Fig 1c).
In addition, consecutive kinetic studies showed suppression of the
gradual time-dependent increase in basal and HGF/SF-induced
VEGF/VPF secretion (Fig 2). These data demonstrate that
dexamethasone intervenes with growth-factor-induced VEGF/
VPF protein expression by cultured epidermal keratinocytes and
immortalized HaCaT cells.
Inhibitory effects of GC on the TGF-a- and HGF/SF-
regulated VEGF/VPF mRNA expression by cultured
keratinocytes In order to establish that GC-mediated
inhibition of induced VEGF/VPF protein synthesis coincides
with comparable changes of speci®c mRNA expression, we
analyzed the effects of different GC on steady-state VEGF/VPF
transcript levels by HaCaT cells. Incubation with increasing
concentrations of dexamethasone resulted in a dose-dependent
inhibition of both TGF-a- and HGF/SF-induced VEGF/VPF
mRNA accumulation (Fig 3a). Analogous to the protein
expression analyses, HGF/SF-mediated VEGF/VPF mRNA
accumulation was seen to be more susceptible to GC treatment.
Whereas dexamethasone almost completely abrogated HGF/SF-
induced mRNA expression, TGF-a-mediated mRNA
accumulation was reduced to nearly one-third (38% 6 11%; p
< 0.02, based on three independent experiments using
dexamethasone at 10±5 M). The dexamethasone effect on
induced VEGF/VPF protein expression is thus re¯ected in
mRNA steady-state expression, suggesting that the inhibitory
properties are potentially mediated at the transcriptional level. This
Figure 1. Dexamethasone inhibits TGF-a- and HGF/SF-induced VEGF/VPF protein expression by cultured keratinocytes. VEGF/VPF
protein concentrations of supernatants derived from con¯uent primary human keratinocytes (HK) or HaCaT cells. (A) HK were cultured in the
absence (w/o GC) or presence (+ GC) of dexamethasone (at 10±6 M) without growth factor stimulation (Ctrl.) or with TGF-a or HGF/SF (each at
100 ng per ml) treatment for 24 h. (B, C) HaCaT cells were left untreated (Ctrl., ®rst bar) or were stimulated with TGF-a (B) or HGF/SF (C) (each at
100 ng per ml) in the presence of increasing concentrations of dexamethasone (at 10±12, 10±9, 10±7, 10±5 M) for 24 h. Values are expressed as ng
secreted VEGF/VPF protein per mg total cellular protein (mean 6 SD, n = 3). Statistical analyses of values obtained from dexamethasone-treated cells
versus those that did not receive GC in the presence of growth factor stimulation were determined on the basis of three independent experiments. ***p
< 0.05, **p < 0.02, *p < 0.001; Student's t test.
Figure 2. HGF/SF-induced VEGF/VPF protein expression is
inhibited by dexamethasone in a time-dependent manner. VEGF/
VPF protein concentration of supernatants derived from con¯uent
HaCaT cell cultures. As delineated, cells were left unstimulated (Ctrl.),
or were incubated with HGF/SF (at 100 ng per ml) for 12, 24, and 48 h
either in the absence or presence (+ GC) of dexamethasone (at 10±7 M).
Values are expressed as ng secreted VEGF/VPF protein per mg total
cellular protein (mean 6 SD, n = 3). Statistical analyses of values
obtained from dexamethasone-treated cells (fourth bar) versus those that
did not receive GC in the presence of HGF/SF stimulation (third bar)
were determined on the basis of three independent experiments.
*p < 0.001; Student's t test.
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effect was also con®rmed with the structurally unrelated GC
clobetasol (Fig 3b) and hydrocortisone (data not shown). Thus, the
inhibitory effects are not restricted to one particular GC only.
Dexamethasone treatment fails to inhibit activation of the
human VEGF/VPF promoter TGF-a and HGF/SF have
been shown previously to induce VEGF/VPF gene expression
predominantly via transcriptional activation (Gille et al, 1997,
1998). We thus hypothesized that GC would mediate their
inhibitory effects through interference with protein±DNA
interactions, critical for growth-factor-induced promoter activity.
Though nuclear transcription factors recruited to transactivate the
VEGF/VPF gene in response to TGF-a and HGF/SF are distinct
(Gille et al, 1998), the TGF-a- and HGF/SF-responsive regions are
both localized between bp ±88 and ±65 with respect to the
transcription start site. In our initial studies utilizing a ±88/+54
VEGF/VPF reporter gene plasmid, however, dexamethasone failed
to inhibit both the TGF-a- and HGF/SF-induced VEGF/VPF
promoter activation (Fig 4a). To explore whether regulatory
elements other than the ±88/±65 bp sequence mediated the GC
effect, a ±1142/+54 bp VEGF/VPF CAT construct was then
analyzed (data not shown). Yet again, the results were comparable
to those obtained with the short plasmid. As induction of a stably
transfected ±2018/+50 bp VEGF/VPF reporter gene construct by
platelet-derived growth factor (PDGF)-BB has been previously
reported to be suppressed by dexamethasone in the mouse
embryonic ®broblast NIH-3T3 cell line (Finkenzeller et al,
1995), we subsequently tested whether a ±2279/+957 bp VEGF/
VPF plasmid (Ikeda et al, 1995) conveyed inhibitory GC effects on
TGF-a- or HGF/SF-induced VEGF/VPF promoter activation
(Fig 4b). Inhibitory effects on induced VEGF/VPF promoter
activity were not observed, however, even with repetitive
dexamethasone treatment or with GC preincubation for different
time periods (1, 16, 24 h). These data demonstrate that regulatory
elements within the ±2279/+957 bp sequence fail to confer
suppression of growth-factor-induced VEGF/VPF gene
transcription in the keratinocyte cell line HaCaT. Whereas these
experiments do not exclude the possibility of GC-dependent
transcriptional repression via interaction through other regulatory
elements, they soundly suggest that post-transcriptional regulatory
events are potentially involved in the observed GC effects on
induced VEGF/VPF gene expression.
Dexamethasone increases VEGF/VPF mRNA turnover in
HaCaT cells To determine whether post-transcriptional
mechanisms can account for inhibitory GC properties on VEGF/
VPF gene expression, the effects of dexamethasone on VEGF/VPF
mRNA turnover by HGF/SF-treated cells were analyzed. After
inhibition of gene transcription by addition of actinomycin D, the
quantity of VEGF/VPF mRNA expression at subsequent time
points was examined and mRNA half-lives were determined by
calculating linear regressions to a log-linear plot of mRNA
expression as a function of time (Fig 5a). These experiments
revealed signi®cant reduction of VEGF/VPF mRNA half-life in
HGF/SF-treated HaCaT cells by coincubation with
dexamethasone (0.25 6 0.10 h vs 0.70 6 0.25 h). Therefore,
dexamethasone-mediated increase in VEGF/VPF mRNA
turnover may lead to repression of HGF/SF-induced VEGF/VPF
mRNA accumulation and subsequent protein expression. To
determine whether GC-dependent suppression of VEGF/VPF
mRNA required de novo protein synthesis, the effect of
dexamethasone on HGF/SF-stimulated HaCaT cells was
evaluated either after preincubation with the protein synthesis
inhibitor cycloheximide or with solvent only (Fig 5b). As reported
previously, cycloheximide itself increased VEGF/VPF mRNA
expression (Frank et al, 1995; Gille et al, 1998), but did not prevent
further upregulation or superinduction by HGF/SF (lane 1).
Whereas HGF/SF-mediated VEGF/VPF mRNA accumulation
(lane 3) was abrogated by coincubation with dexamethasone (lane
4), no discernable differences in induced VEGF/VPF expression
were detected in response to dexamethasone after preincubation
with cycloheximide (lane 2), suggesting the need for GC-
dependent protein expression to exert inhibitory effects.
DISCUSSION
The contribution of blood vessels to in¯ammation has long been
recognized (Lingen, 2001), presenting with functional changes such
as microvascular hyperpermeability and activation of the endothe-
lium, as well as structural changes, including enhanced vasculariza-
tion by convoluted microvessels (Braverman and Sibley, 1982;
Braverman, 1983). Whereas in¯ammatory processes rely on the
coordinated interplay of numerous distinct cell types and soluble
mediators in a spatial and temporal fashion, compelling evidence
has been provided recently closely linking angiogenesis to in¯am-
mation as well as supporting the assumption of a mutual
codependence (Jackson et al, 1997; Majno, 1998). Aside from
sole correlation of tissue in¯ammation with upregulated VEGF/
VPF expression as one of the predominant regulators of
angiogenesis, transgenic VEGF/VPF overexpression has been
shown to increase microvascular density and to enhance leukocyte
rolling and adhesion, thereby potentially facilitating leukocyte
in®ltration in the early phase of in¯ammation (Detmar et al, 1998).
Importantly, therapeutic strategies that are directed against VEGF/
VPF bioavailability (Miotla et al, 2000; Sone et al, 2001) or that are
shown to preferentially act via antiangiogenic mechanisms (de
Bandt et al, 2000) effectively inhibit chronic in¯ammation.
Figure 3. GC prevent accumulation of VEGF/VPF mRNA in a
concentration-dependent fashion in TGF-a- and HGF/SF-treated
HaCaT cells. Northern blot analyses of total RNA (20 mg per lane)
extracted from con¯uent cell cultures. (A) HaCaT cells were incubated
with TGF-a (left panel) or HGF/SF (right panel; each at 100 ng per ml)
in the absence (®rst lane of each panel) or presence of increasing
concentrations of dexamethasone (at 10±9, 10±7, 10±5 M) for 6 h prior to
extraction. (B) As indicated, cells were left untreated (media change
only, ®rst lane), or were incubated with either TGF-a (left panel) or
HGF/SF (right panel; each at 100 ng per ml) in the absence or presence
of clobetasol (at 10±7 M) for 6 h prior to extraction. The lower panels
display an image of the respective ethidium-bromide-stained nylon
membrane to demonstrate even loading and transfer. Results were
con®rmed in three independent sets of experiments.
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We therefore hypothesized that GC as established anti-in¯am-
matory agents mediate therapeutic ef®cacy in cutaneous in¯am-
mation in part through interference with inducible VEGF/VPF
expression by epidermal keratinocytes. In order to test the
hypothesis, we studied the effects of different GC on TGF-a-
and HGF/SF-regulated VEGF/VPF expression, representing two
distinct molecular pathways in mediating cutaneous angiogenesis.
Our studies reveal inhibitory GC effects on induced VEGF/VPF
protein synthesis by primary keratinocytes and immortalized
HaCaT cells. Both TGF-a- and HGF/SF-mediated VEGF/VPF
expression are repressed in a concentration- and time-dependent
fashion. These ®ndings are in line with previous studies, showing
GC-mediated inhibition of PDGF- or hypoxia-induced VEGF/
VPF expression (Heiss et al, 1996; Nauck et al, 1998). Whereas
PDGF-induced production was readily repressed, dexamethasone
only marginally inhibits hypoxia-mediated VEGF/VPF synthesis.
The latter inhibitory effects are thought to account in part for
dexamethasone-mediated suppression of brain-tumor-associated
vascular hyperpermeability and edema formation (Heiss et al,
1996; Machein et al, 1999). Despite the fact that GC have been
found to suppress VEGF/VPF expression in response to diverse
stimuli (Harada et al, 1994; Palacio et al, 1997) and in different cell
types (Gonzalez et al, 1999; Saadeh et al, 1999), the molecular
mechanisms involved in VEGF/VPF suppression by GC have not
been determined yet.
It was thus an additional aim of our study to explore control
mechanisms that convey GC-mediated inhibition of induced
VEGF/VPF gene expression. Transcriptional regulation has been
established to be a key control point of VEGF/VPF protein
synthesis in response to many stimuli. We and others have
Figure 4. Inhibitory effects of
dexamethasone on the regulated VEGF/VPF
expression are not conveyed by a ±2279/
+957 bp fragment of the VEGF/VPF
promoter. (A) Analysis of CAT expression
derived from a transiently transfected ±88/+54 bp
VEGF/VPF promoter-based CAT construct.
HaCaT cells were cultured in the absence (w/o
GC) or presence (+ GC, at 10±5 M) of
dexamethasone without growth factor stimulation
(Ctrl., ®rst panel), or with TGF-a or HGF/SF
(each at 100 ng per ml) treatment for 16 h. (B)
Analysis of luciferase expression derived from a
transiently transfected ±2279/+957 bp VEGF/VPF
promoter-based luciferase construct. The
transcriptional activation experiments were
con®rmed in three independent sets of
experiments. Values represent the mean 6 SD of
triplicate assays.
Figure 5. Dexamethasone decreases VEGF/
VPF mRNA stability, apparently
independently of de novo protein synthesis.
Northern blot analyses of total RNA (20 mg per
lane) extracted from con¯uent HaCaT cell
cultures. (a) Incubation with HGF/SF (100 ng per
ml) for 16 h either in the absence (in the center) or
presence (on the right) of dexamethasone (10±5 M)
and 1, 2, and 3 h after addition of actinomycin D
(7.5 mg per ml). Total RNA was analyzed with
labeled VEGF/VPF (upper image) or GAPDH
cDNA probe (center). The lower panels display an
image of the respective ethidium-bromide-stained
nylon membrane. Log-linear plot (left) of
corrected VEGF/VPF mRNA expression (%)
versus time (h) including calculated linear
regression lines of the different experimental
procedures: treatment with (d) or without (s)
dexamethasone. Calculated half-lives on the basis
of two independent experiments: (d) 0.25 6
0.10 h; (s) 0.70 6 0.25 h. (b) Preincubation with
cycloheximide (CHX, 7.5 mg per ml; lanes 1, 2)
or solvent only (DMSO 0.1%, lanes 3, 4) for 1 h,
followed by stimulation with HGF/SF (100 ng
per ml) for 6 h either in the absence (lanes 1, 3)
or presence (10±5 M, lanes 2, 4) of dexa-
methasone. The data displayed are representative
of three that were performed revealing equivalent
results.
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identi®ed a GC-rich 5¢-regulatory responsive region localized
between bp ±88 and ±65 of the VEGF/VPF gene that is critical for
basal and induced expression by several growth factors
(Finkenzeller et al, 1997), including the expression by TGF-a
and HGF/SF (Gille et al, 1997, 1998). In addition, a major response
element necessary for hypoxia-induced VEGF/VPF gene tran-
scription was identi®ed far more upstream between bp ±979 and
±959 (Liu et al, 1995; Forsythe et al, 1996). Besides a rapid and
lasting transcriptional activation, hypoxia-mediated VEGF/VPF
gene expression was demonstrated to depend on a gradual increase
in mRNA stability (Ikeda et al, 1995; Levy et al, 1996). Conversely,
the majority of previous investigations have shown that growth-
factor- and cytokine-induced VEGF/VPF expression is not
accounted for by prolongation of VEGF/VPF mRNA half-life,
including that induced by HGF/SF (Gille et al, 1998) and TGF-a
(unpublished observation). It was our initial hypothesis that
dexamethasone would interfere with VEGF/VPF gene transcrip-
tion through interaction with nuclear factors, binding to the GC-
rich region in close proximity to the transcription start site. This
assumption was supported by previous ®ndings, demonstrating
transrepression of VEGF/VPF promoter activity by both von
Hippel±Lindau and p53 tumor suppressor gene product via
interaction with this region in close proximity to the transcription
start (Mukhopadhyay et al, 1997; Zhang et al, 2000). GC were
ineffective in repressing reporter gene constructs spanning wide 5¢
sequences between bp ±2279 and +957 in our transcriptional
activation studies, however. These data indicate that suppression of
TGF-a- and HGF/SF-induced VEGF/VPF gene expression by
dexamethasone is not mediated by common 5¢-regulatory
sequences, including those responsible for growth-factor-induced
promoter activation. Thus, transcriptional regulation may not be
considered a predominant control point in GC-mediated suppres-
sion of keratinocyte VEGF/VPF protein synthesis, though
transrepression via other regulatory regions is not fully excluded
as possible mechanisms.
Intensive research on GC-mediated gene regulation has identi-
®ed several modes of transcriptional control (Karin, 1998).
Generally, GC mediate their biologic effects through a speci®c
glucocorticoid receptor (GR), a DNA-binding protein that
translocates into the nucleus upon ligand-binding. In line with
this concept, inhibitory effects of GC on VEGF/VPF gene
expression have been previously shown to be reversed by speci®c
GR antagonists (Gloddek et al, 1999; Machein et al, 1999). Among
different likely means of GC action, transcriptional interference via
interactions of GR with transactivating transcription factors (e.g.,
NF-kB, AP-1) is considered a central molecular mechanism (Karin,
1998). Conversely, neither nuclear factors currently known to
interact with GR nor transcription factors critical for growth-
factor-induced VEGF/VPF gene transcription are apparently
involved in suppression of HGF/SF- or TGF-a-induced VEGF/
VPF protein synthesis by GC.
Whereas previously attention on inhibitory GC effects has
mainly focused on transcriptional mechanisms, more recently post-
transcriptional and translational modes of GC action, employed to
negatively regulate the expression of responsive genes, have been
identi®ed (Newton, 2000). In a number of instances, GC were
shown to inhibit gene expression at the level of mRNA half-life
(Peppel et al, 1991; Garcia-Gras et al, 2000). For the ®rst time, we
here provide evidence that GC-mediated inhibition of VEGF/VPF
gene expression may be mediated via increased mRNA turnover.
In GC-treated cells, VEGF/VPF mRNA message was rapidly
degraded within less than 2 h. As protein synthesis inhibition by
cycloheximide did not attenuate or block HGF/SF-superinduced
mRNA expression in the presence of dexamethasone, dexametha-
sone-dependent suppression of VEGF/VPF mRNA apparently
requires de novo protein synthesis, suggesting the necessity for GC-
inducible gene expression.
The decay of a particular mRNA may depend on several distinct
transacting proteins that interact with speci®c stability-in¯uencing
mRNA sequences, among which the cap structure and poly(A) tail
as well as the untranslated regions (UTRs) at the 5¢ and 3¢ end are
of key importance for degradation control (Ross, 1996). GC-
mediated mRNA destabilization has been demonstrated in the past
to involve RNA±protein interactions with both the 3¢- and 5¢-
UTR (Peppel et al, 1991; Poon et al, 1999). Mostly, GC-
destabilizing sequences have been mapped to regions containing
multiple adelylate- and uridylate-rich elements (Hoover and Floros,
1999; Garcia-Gras et al, 2000). Further expanding on the diversity
of regulatory mechanisms that control mRNA half-life, GC-
mediated destabilizing activity may require de novo protein synthesis
(Lasa et al, 2001) or may be present despite protein inhibition
(Peppel et al, 1991).
VEGF/VPF gene expression has been shown to be subject to
both transcriptional and post-transcriptional regulation. Control of
VEGF/VPF half-life is evidently mediated by both stability and
instability elements (Ikeda et al, 1995; Levy et al, 1996). Under
normal conditions, multiple destabilizing mRNA elements within
the 5¢-UTR, coding region, and 3¢-UTR seem to assure tight
regulation of VEGF/VPF gene expression (Levy et al, 1996;
Dibbens et al, 1999). In opposition, an increase in VEGF/VPF
mRNA half-life under hypoxic conditions is conferred by hypoxia-
inducible protein binding to stabilizing sequences of the 3¢-UTR
(Claffey et al, 1998; Levy et al, 1998; Pages et al, 2000).
Interestingly, compared to other stimuli, hypoxia-induced
VEGF/VPF mRNA accumulation is less sensitive to GC-mediated
inhibition (Heiss et al, 1996; Machein et al, 1999). It is thus
tempting to consider that VEGF/VPF expression induced by
stimuli that signi®cantly increase mRNA half-life, such as hypoxia,
is less receptive to GC-mediated suppression due to competing
effects on mRNA stability. This assumption is also conceivable as
mRNA stabilizing elements may be distinct from those conveying
GC-mediated increase in mRNA turnover (Peppel et al, 1991).
Together, our studies identify VEGF/VPF upregulation by
epidermal keratinocytes as a putative target of GC action in
cutaneous in¯ammation. We provide evidence that VEGF/VPF
mRNA destabilization may represent a mechanism by which GC
inhibit growth-factor-regulated VEGF/VPF gene expression by
keratinocytes. Mapping the GC-responsive regions and identi®ca-
tion of involved RNA-binding proteins may facilitate ®nding novel
opportunities to inhibit VEGF/VPF synthesis by means of
enhanced mRNA turnover.
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